医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

USD

Aston Sci. Raises USD 22.7 Million Series C Funding

Aston Sci. Raises USD 22.7 Million Series C Funding

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Aston Sci. Raises USD

2022年03月04日

U.S. Nurses Encouraged to Apply: Aster Guardians Global Nursing Awards Deadline Extended to February 15: First Prize $250,000 USD ＆ Nine Additional Awards

U.S. Nurses Encouraged to Apply: Aster Guardians Global Nursing Awards Deadline Extended to February 15: First Prize $250,000 USD ＆ Nine Additional Awards

ヘルスケアヘルス一般マネージド・ケア医療管理病院　 TimeLine: Aster Guardians Global Nursing Awards Deadline Extended to February 15 First Prize Nine Additional Awards Nurses Encouraged to Apply USD

2022年02月01日

MFine Raises USD 48 million in Series C to Build India’s Largest Virtual Hospital

MFine Raises USD 48 million in Series C to Build India’s Largest Virtual Hospital

ヘルスケアヘルス一般マネージド・ケア医療機器病院　 TimeLine: 48 million in Series C to Build India’s Largest Virtual Hospital MFine Raises USD

2021年09月30日

EdiGene Raises Approximately USD 62 Million in Series B Plus Financing and Expands Operation Locations to Advance and Scale Up Clinical Translation of Gene Editing Technologies

EdiGene Raises Approximately USD 62 Million in Series B Plus Financing and Expands Operation Locations to Advance and Scale Up Clinical Translation of Gene Editing Technologies

バイオテクノロジーヘルスケアヘルス一般　 TimeLine: EdiGENE Raises Million in Series B Plus Financing and Expands Operation Locations to Advance and Scale Up Clinical Translation of Gene Editing Technologies USD

2021年04月21日

PharmCADD Raised USD 16m in Series B Funding

PharmCADD Raised USD 16m in Series B Funding

バイオテクノロジーヘルスケア製薬　 TimeLine: PharmCADD Raised USD

2021年04月19日

Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD

Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD

その他ヘルスバイオテクノロジーヘルスケアヘルス一般製薬　 TimeLine: $322 million Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for USD

2020年12月21日

Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USD

Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USD

バイオテクノロジーヘルスケア医療機器腫瘍学製薬　 TimeLine: $562 million Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately USD

2020年09月08日